Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Cash from Operations (2018 - 2025)

Historic Cash from Operations for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to $40.8 million.

  • 10x Genomics' Cash from Operations rose 70428.28% to $40.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $136.0 million, marking a year-over-year increase of 194156.66%. This contributed to the annual value of $136.0 million for FY2025, which is 194156.66% up from last year.
  • 10x Genomics' Cash from Operations amounted to $40.8 million in Q4 2025, which was up 70428.28% from $43.2 million recorded in Q3 2025.
  • Over the past 5 years, 10x Genomics' Cash from Operations peaked at $43.2 million during Q3 2025, and registered a low of -$26.2 million during Q3 2021.
  • In the last 5 years, 10x Genomics' Cash from Operations had a median value of -$481000.0 in 2021 and averaged $3.6 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first tumbled by 64368.59% in 2022, then soared by 70428.28% in 2025.
  • Over the past 5 years, 10x Genomics' Cash from Operations (Quarter) stood at $5.8 million in 2021, then skyrocketed by 136.4% to $13.7 million in 2022, then soared by 87.7% to $25.8 million in 2023, then tumbled by 126.2% to -$6.7 million in 2024, then skyrocketed by 704.28% to $40.8 million in 2025.
  • Its last three reported values are $40.8 million in Q4 2025, $43.2 million for Q3 2025, and $17.7 million during Q2 2025.